Xeris Pharmaceuticals

Yahoo Finance • 2 months ago

H.C. Wainwright assumes coverage on Xeris Pharmaceuticals stock with Buy rating

Investing.com - H.C. Wainwright has assumed coverage on Xeris Pharmaceuticals (NASDAQ:XERS), currently trading at $7.20 with a market capitalization of $1.16 billion, with a Buy rating and a $10.00 price target, according to a research n... Full story

Yahoo Finance • 2 months ago

Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev

Earnings Call Insights: Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 MANAGEMENT VIEW * John P. Shannon, CEO, reported "the strong momentum we established in the first quarter continued into the second quarter, driving another period o... Full story

Yahoo Finance • 2 months ago

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance

Xeris Biopharma Holdings Inc (NASDAQ:XERS [https://www.chartmill.com/stock/quote/XERS]) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction in pre-market trading. The comp... Full story

Yahoo Finance • 6 months ago

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the... Full story

Yahoo Finance • 2 years ago

Xeris Biopharma CEO reveals impact of CSO's departure and exciting future plans

New York --News Direct-- Xeris Biopharma Holdings Xeris Biopharma CEO Paul Edick joined Proactive's Natalie Stoberman to share the resignation of the company's Chief Scientific Officer and Founder Dr. Steven Prestrelski as he transitions... Full story

Yahoo Finance • 2 years ago

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Novel formulation of levothyroxine sodium (SC injection) to potentially mitigate many of the challenges associated with oral formulations of levothyroxine. Phase 2 study to establish the average once-weekly dose, accrue additional safety... Full story

Yahoo Finance • 2 years ago

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

CHICAGO, April 18, 2023--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a rang... Full story

Yahoo Finance • 2 years ago

Subdued Growth No Barrier To Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) With Shares Advancing 61%

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares have continued their recent momentum with a 61% gain in the last month alone. But the gains over the last month weren't enough to make shareholders whole, as the share price is still down... Full story